Bone Biology
A 72-year-old woman with severe osteoporosis and a history of vertebral fractures is being considered for treatment with romosozumab, a monoclonal antibody that inhibits sclerostin. She asks about how this medication works differently from her previous bisphosphonate therapy. Her bone mineral density T-score is -3.2 at the spine. Regarding sclerostin and bone metabolism:
Mark each as TRUE or FALSE
Sclerostin is a glycoprotein produced primarily by osteocytes encoded by the SOST gene; it acts as a...
Loss-of-function mutations in the SOST gene cause sclerosteosis and Van Buchem disease, characterize...
Sclerostin is produced by osteoclasts; it activates the Wnt signaling pathway; sclerostin promotes o...
Romosozumab is a humanized monoclonal antibody against sclerostin; by inhibiting sclerostin, it rele...
Clinical effects of romosozumab include increased bone formation markers (P1NP), decreased bone reso...
Answer the questions to see explanations
Click T (True) or F (False) for each option